MetallobodiesTM: Hybrid Technology for Biomolecular Recognition
Tailored detection projects designed for our customers
Our technology
Melisa Platform
Our metallobodiesTM are based on Hybrid Mimetic Antigens and allow rapid and specific detection of multiple targets
MEtaLlic Immuno-Scaffold Assay is a versatile platform for biomolecular recognition…
MELISA offers endless possibilities in biomolecular recognition
1
Batch-to-Batch Reproducibility
2
Robustness and Stability
3
Versatility
4
Tailored for each need
5
Fast and Cost-effective manufacturability
6
Ethical and sustainable
Binder and reporter in the same molecule
Binding protein sequence is engineered specifically for each target
The metal cluster is used as reporter: photoluminescent, catalytic, electroactive, magnetic
Detection aplications and use cases
Antibodies
Antigens
Proteins
Cancer cells
Nanobodies
More coming
Solutions
Antibody Detection
The platform based on our metallobodies allows rapid and specific detection of multiple antibodies.
Tailored Detectors for Diverse specific Targets
Focus On
Autoimmune Disorders
Detection of disease-specific autoantibodies to support diagnosis and patient stratification.
Multiplexed sensor technology for simultaneous detection of key autoimmune targets.
Intellectual property
Solid Intellectual Property Position
The patent, property of CIC biomaGUNE, has been exclusively licensed to TALDEKI Biosolutions, indefinitely and across all covered territories.
Protects reagents, production process, and uses therof.
Team
Meet us
We Are a Multidisciplinary Team Turning Science into Impact
CEO
Luiza I. Hernandez
PhD in Chemistry (MSU, USA).
Scientist–entrepreneur with deep expertise in molecular diagnostics, biosensors, and nucleic acid/protein engineering. Proven leader in translating advanced biomolecular technologies into impactful diagnostic and therapeutic innovations.
Author of 25+ peer-reviewed publications and inventor on 8 patents.
Co-founder of three biotech start-ups with over a decade of C-level experience.
Strategic Advisor
Marcos Simón
Experienced entrepreneur with a strong background in company creation.
Technology Transfer Officer at CIC biomaGUNE and scientist with multiple publications and patents.
Skilled in advising and leading technology transfer processes.
Mission
Our mission is to build the next generation of high-precision diagnostic and therapeutic tools.
Using our Metallobodies® platform technology, we create versatile nanosensors and biologics that improve disease detection, enable multiplex biomarker analysis, and open new avenues in targeted therapy. We partner with industry and clinical teams to transform unmet medical needs into validated, deployable solutions.
Vision
We envision a future where Metallobodies—smart, programmable, multifunctional binders—become foundational tools in medicine, thus enabling earlier diagnosis, personalized treatment, and smarter therapeutic design across the entire continuum of care.
Supported by
Contact
Let's talk
If you would like more information, please contact us. We would be happy to arrange a meeting to discuss further.